The California Supreme Court ruled that settlement agreements between pharmaceutical companies that keep cheaper, generic drugs off the market may be illegal if they include excessive cash payments.
Sanofi said Thursday Brandicourt, 59, will start on April 2. He has been Bayer HealthCare's...
The company announced the overhaul of its HealthCare, CropScience and other operations in a...
The program is based on Proteros' structure-guided lead discovery platform which combines...
Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of Xofigo. As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo.
Bayer HealthCare has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, for the treatment of hemophilia A in children and adults.
Two medicines Bayer HealthCare Pharmaceuticals Inc. is testing for respiratory disorders will get priority review by U.S. regulators and other benefits under a 2012 program to boost development of new antibiotics.
Merck has completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion.
German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The Leverkusen-based company that invented aspirin said Thursday the move would be part of an effort to focus the group on its health care and crop science businesses.
The Department of Justice filed a court motion against the German conglomerate over its advertisements for Phillips' Colon Health, which claims to prevent diarrhea, constipation, gas and bloating. Federal officials say the company does not have reliable scientific evidence to support those claims.
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
Bayer today announced the appointment of Malini Moorthy as Head of the Litigation Department in the United States, effective July 30. She succeeds Kaspar Stoffelmayr, whose three-year assignment ended and has rejoined Bartlit Beck Herman Palenchar & Scott LLP.
Compugen Ltd. has achieved the initial milestone in the cancer immunotherapy collaboration it entered last year with Bayer HealthCare. The collaboration provides for the development and commercialization of therapeutic antibodies against two checkpoint protein candidates discovered by Compugen.
Bayer HealthCare LLC Animal Health is pleased to announce the launch of quellin (carprofen) soft chewable tablets to help alleviate the pain associated with canine osteoarthritis, one of the most common causes of chronic pain in dogs.
Bayer HealthCare announced today that the FDA has approved a new indication for Gadavist (gadobutrol) injection for intravenous use with MRI of the breast to assess the presence and extent of malignant breast disease.
In line with his own wishes, the contract of Dr. Marijn Dekkers will be extended by just two years on expiration of the initial five-year period. Dekkers cited family reasons for extending his contract only until the end of 2016.
In a move to expand significantly its portfolio of leading solutions for peripheral interventions, Boston Scientific Corporation has entered into a definitive agreement to acquire the Interventional Division of Bayer AG for $415 million in cash, including fees for transitional services.
By joining the portal, Bayer HealthCare is supporting efforts of the European Medicines Agency (EMA) to increase the transparency of data from clinical studies. As a member company of the pharmaceutical trade associations EFPIA and PhRMA, Bayer is following their declared principles on responsible clinical trial data sharing.
Bayer HealthCare announced today that the FDA has approved a new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.
Bayer AG says it plans to buy Merck's consumer care business, whose products include the Coppertone suncare range, Claritin allergy medicine and the Dr. Scholl's footcare products, for $14.2 billion.
A Washington University research project that provides free birth control to the poor and uninsured is under scrutiny for its off-label use of a contraceptive insert.
Bayer AG says its net profit jumped by almost a third last year to 3.19 billion euros ($4.35 billion) as sales hit a record high.
Bayer HealthCare to Invest in Manufacturing Operations as Next Step in Recent Animal Health Business AcquisitionJanuary 20, 2014 2:57 pm | News | Comments
Bayer HealthCare LLC has announced that the company will be improving efficiency and investing in its manufacturing operations in Missouri. The company will combine and transfer operations from three locations in the St. Joseph area to one beginning this year.
Regeneron Pharmaceuticals and Bayer HealthCare today announced an agreement to jointly develop an innovative antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a potential combination therapy with EYLEA (aflibercept) for the treatment of wet age-related macular degeneration (wet AMD).
Germany's Bayer AG is set to acquire cancer drug maker Algeta ASA after raising its offer for the Norwegian-based company to nearly $2.9 billion. The two firms said Thursday drug and chemical company Bayer will make a cash offer of 362 kroner ($59.24) per Algeta share.
Moberg Pharma AB has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources.
Norway-based cancer drug maker Algeta ASA says it has received a preliminary takeover offer from Germany's Bayer AG that values the company at about $2.4 billion. Algeta said in a statement Tuesday that the offer is for 336 kroner ($55.11) per share; the company has nearly 44 million shares.
The FDA has expanded approval of a Bayer drug to treat patients with thyroid cancer. Bayer's pill Nexavar is already approved to treat kidney cancer and liver cancer that cannot be surgically removed. Now the FDA has approved the drug to treat cancerous growth of the thyroid gland, which is located in the neck.
Drug and materials company Bayer AG says net profit rose 42 percent as sales increased for its new drugs aimed at preventing blood clots and treating the eye disease macular degeneration, while one-time expenses dropped. Net profit reached $1.01 billion.
- Page 1